Corticosteroid skin atrophogenicity: assessment methods.

Area of Science:

• Dermatology
• Pharmacology
• Clinical Trials

Background:

• Skin atrophy, characterized by fragile skin, bruising, telangiectasia, and striae distensae, is a common side effect of topical corticosteroids.
• Predicting the atrophogenicity of topical corticosteroids is essential for patient safety and effective treatment.

Purpose of the Study:

• To review existing literature on methods for predicting topical corticosteroid atrophogenicity.
• To propose a standardized assay method for evaluating the atrophogenicity potential of topical corticosteroids in humans.

Main Methods:

• Literature review of current assay methodologies for topical corticosteroid atrophogenicity.
• Identification of key variables requiring standardization, including reference corticosteroids, anatomical sites, administration methods, and quantification techniques.

Main Results:

• Current methods for predicting topical corticosteroid atrophogenicity lack standardization.
• Significant variability exists in assay design, reference standards, and outcome measures across studies.

Conclusions:

• A standardized assay method is necessary to ensure reliable and reproducible assessment of topical corticosteroid atrophogenicity.
• Implementation of a standardized assay will facilitate more accurate risk-benefit assessments for topical corticosteroid therapies.